Acorda Therapeutics, Inc.
ACOR
Κατάταξη σε μετοχές
#39162
Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering,... Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing treatments for conditions affecting the nervous system, primarily within the United States. Its current product offerings include Ampyra (dalfampridine), an oral medication prescribed to enhance walking ability in individuals with multiple sclerosis (MS). The company also distributes Inbrija in Europe, which is used to manage "OFF" periods experienced by Parkinson's disease patients. Globally, Ampyra is recognized and sold as Fampyra across Europe, Asia, and the Americas. Beyond its existing products, Acorda is actively advancing several experimental therapies: ARCUS for the management of acute migraine attacks, rHIgM22 which has successfully completed Phase I clinical trials for MS, and Cimaglermin alfa, currently being investigated for patients with heart failure. The company holds a licensing and collaborative agreement with Biogen Inc. for the ongoing development and market distribution of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and operates from its headquarters in Ardsley, New York.
Τιμή μετοχής
$0.879
Τελευταίος συγχρονισμός: 2024-05-07
Κεφαλαιοποίηση
$582.38K
Αλλαγή (1 ημέρα)
9.88%
Αλλαγή (1 έτος)
8,690.00%
Χώρα
US
Εμπόριο Acorda Therapeutics, Inc. (ACOR)
Κατηγορία
Healthcare
Κέρδη για την Acorda Therapeutics, Inc. (ACOR)
Κέρδη τον Mar 2024 TTM: $-304.44M
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Acorda Therapeutics, Inc., τα τρέχοντα κέρδη της εταιρείας είναι $-304.44M. Το 2022, η εταιρεία παρουσίασε κέρδη $-35.25M, αύξηση σε σχέση με των κερδών του 2021 που ήταν $-109.07M. Τα κέρδη που εμφανίζονται σε αυτή τη σελίδα είναι πριν από τόκους και φόρους, γνωστά και ως EBIT.
Ιστορικό κερδών για την Acorda Therapeutics, Inc. από 2016 έως 2026
Κέρδη στο τέλος κάθε έτους
| Έτος | Κέρδη | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $-304.44M | 2.84% |
| 2023 | $-296.02M | 739.85% |
| 2022 | $-35.25M | -67.69% |
| 2021 | $-109.07M | 1.31% |
| 2020 | $-107.67M | -60.74% |
| 2019 | $-274.25M | -1,442.84% |
| 2018 | $20.42M | -108.11% |
| 2017 | $-251.89M | 495.92% |
| 2016 | $-42.27M | 0.00% |
Κέρδη παρόμοιων εταιρειών ή ανταγωνιστών
| Εταιρεία | Κέρδη | Διαφορά Κερδών | Χώρα |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | -679.61% |
IN
|
